Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fresh from the biologic pipeline--2010.

Literature DB >> 21390016

Fresh from the biologic pipeline--2010.

Jim Kling.

Abstract

Mesh：

Substances：
Biological Products

Year: 2011 PMID： 21390016 DOI： 10.1038/nbt.1793

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

7 in total

1. Transgenic salmon inches toward finish line.

Authors: Jeffrey L Fox
Journal: Nat Biotechnol Date: 2010-11 Impact factor: 54.908

2. Shire's replacement enzymes validate gene activation.

Authors: Nuala Moran
Journal: Nat Biotechnol Date: 2010-11 Impact factor: 54.908

Review 3. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors: Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal: Nat Rev Drug Discov Date: 2010-10-29 Impact factor: 84.694

Review 4. Assessing the bioequivalence of biosimilars The Retacrit case.

Authors: H Schellekens
Journal: Drug Discov Today Date: 2009-02-14 Impact factor: 7.851

5. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors: W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal: Cell Date: 1997-04-18 Impact factor: 41.582

6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors: Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal: N Engl J Med Date: 2010-07-29 Impact factor: 91.245

7. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors: Kunitomo Adachi; Kenji Chiba
Journal: Perspect Medicin Chem Date: 2007-09-06

7 in total

6 in total

Fresh from the biologic pipeline--2010.

1. Transgenic salmon inches toward finish line.

2. Shire's replacement enzymes validate gene activation.

Review 3. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Review 4. Assessing the bioequivalence of biosimilars The Retacrit case.

5. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

7. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

1. Reinventing clinical trials.

Review 2. Genome editing revolutionize the creation of genetically modified pigs for modeling human diseases.

3. Industry access to the literature.

Review 4. Decoding mechanisms by which silent codon changes influence protein biogenesis and function.

Review 5. Bringing rigour to translational medicine.

6. Recombinant human factor IX produced from transgenic porcine milk.